Herpes simplex vaccine live recombinant - MedImmune Vaccines

Drug Profile

Herpes simplex vaccine live recombinant - MedImmune Vaccines

Alternative Names: AD-472; R 7017; R 7020

Latest Information Update: 29 Sep 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune Vaccines; sanofi pasteur
  • Developer MedImmune Vaccines
  • Class Viral vaccines; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 29 Sep 2004 Discontinued - Preclinical for Herpes simplex virus infections in USA (unspecified route)
  • 30 Aug 2004 Aventis has merged with Sanofi-Synthélabo to form Sanofi-Aventis
  • 03 Dec 2001 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top